Mark Daniels, PhD

Photo of Mark Daniels, PhD

Molecular Microbiology and Immunology


Associate Professor
Molecular Pathogenesis and Therapeutics Graduate Program



A healthy individual can mount an immune response to pathogens and tumors while avoiding an autoimmune attack on normal tissues. Our lab studies how signal transduction pathways regulate lymphocyte development, activation and tolerance.

We are exploring:

  • How deregulation of signaling pathways in developing lymphocytes leads to the development of hematological cancers.
  • We are part of a multidisciplinary consortium who’s goals are to use a precision medicine-based approach to:
    • develop tumor-specific delivery of our novel anti-leukemia/lymphoma drugs.
    • utilize a high throughput neoantigen discovery platform to improve immunotherapy outcomes for multiple types of cancer.
  • How lymphocyte receptors signal the programs that distinguish immune protection from immune pathology for infectious disease.

Lab members

Academic Information

Associate Professor
Molecular Pathogenesis and Therapeutics Graduate Program


NW301 Medical Sciences Bldg.
Columbia, MO 65212
United States

P. 573-884-1659

Research Interests

  • T and B cell biology
  • Tumor immunotherapy
  • Leukemia
  • Lymphoma
  • Autoimmunity
  • Immune Response to Pathogens
  • Signal Transduction
  • Biochemistry
  • Immunology
  • Drug Development

Areas of Expertise

  • T and B cell development and activation
  • T cell engineering
  • Lymphocyte signaling, oncology and cell biology

Education & Training

Post-Graduate School

2002, PhD, University of Minnesota

In the News


Download All Publications Download